{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"69"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"18"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"title":"Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"89"}],"units":"Participants"}],"description":"Cardiac ejection fraction was assessed by transthoracic echocardiogram (ECHO) or multigated acquisition (MUGA). Participants who developed signs/symptoms of congestive heart failure (CHF) at any point during the study were required to have an evaluation of LVEF measurements by ECHO or MUGA and were monitored per institutional guidelines.\n\nParticipants were considered as having a LVEF abnormality if the worst post-value was CTCAE Grade 2, 3 or 4 according to the following classification:\n\nGrade 0: Non-missing value below Grade 2. Grade 2: LVEF between 40% and 50%, inclusive, or absolute change from baseline between -10% and \\< -20%.\n\nGrade 3: LVEF between 20% and 39%, inclusive, or absolute change from baseline ≤ -20%.\n\nGrade 4: LVEF lower than 20%. Baseline was defined as the last available and valid assessment before or on the start date of study intervention.","groups":[{"description":"Treatment-naïve participants with BRAF V600E-mutant metastatic NSCLC were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"OG000","title":"Treatment-Naive"},{"description":"Patients who had received 1) first-line treatment with standard platinum-based chemotherapy, or 2) first-line treatment with an anti-PD-1/PD-L1 inhibitor given alone, or in combination with platinum-based chemotherapy, or in combination with immunotherapy (eg, ipilimumab) with or without platinum-based chemotherapy were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID was to be administered in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"OG001","title":"Previously Treated"},{"description":"Sum of all participants in the Study C4221008 (ARRAY-818-202)","id":"OG002","title":"Total"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis Population included all participants who received at least 1 dose of study intervention and had both baseline and post-baseline LVEF values. Number of participants analyzed signifies number of participants who were evaluable for this outcome measure. Number analyzed refers to number of participants evaluable for specified rows of categories.","reportingStatus":"POSTED","timeFrame":"Screening, Cycle 2 Day 1 ±3 Days, Every 12 Weeks ±7 Days, and EOT ±3 Days (Up to 36 Months)","title":"Number of Participants With the Worst Post-baseline Left Ventricular Ejection Fraction (LVEF) Values Based on CTCAE Grade","type":"SECONDARY","unitOfMeasure":"Participants"}